cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
== External links == Angiogenesis for Heart Disease from Angioplasty.Org Angiogenesis - The Virtual Library of Biochemistry, Molecular Biology and Cell Biology Visualizing Angiogenesis with GFP NCI Understanding Cancer series on Angiogenesis
(The capital Greek letter "Δ" (delta) corresponds to Roman "D", for Double bond). Thus, for example, the 20-carbon arachidonic acid is Δ5,8,11,14, meaning that it has double bonds between carbons 5 and 6, 8 and 9, 11 and 12, and 14 and 15. In the context of human diet and fat metabolism, unsaturated fatty acids are often classified by the position of the double bond closest between to the ω carbon (only), even in the case of multiple double bonds such as the essential fatty acids. Thus linoleic acid (18 carbons, Δ9,12), γ-linolenic acid (18-carbon, Δ6,9,12), and arachidonic acid (20-carbon, Δ5,8,11,14) are all classified as "ω−6" fatty acids; meaning that their formula ends with –CH=CH–CH2–CH2–CH2–CH2–CH3. Fatty acids with an odd number of carbon atoms are called odd-chain fatty acids, whereas the rest are even-chain fatty acids. The difference is relevant to gluconeogenesis.
After optimizing the concentration of graphene oxide concentration and anisotropic porous structure, tensile tests were performed. It was found that MGCA could recover 99.8% and 96.3% when compressed to 60% and 90% strain, respectively. SEM images showed that due to its unique structure, MCGA pore walls were able to wrinkle and fold during compression. Another unique characteristic of this material is its absorption capacity of 80-197 times its weight towards hydrophobic compounds, such as oils and chemical solvents. On the contrary, less effort has been made to study the stretchability of porous carbons. Gao, et al. synthesized a long-range lamellar scaffold composed of chitosan and graphene oxide via bidirectional freezing, freeze drying, and annealing. The result is a material with density of 11 mg cm−3 and porosity of about 99.4%. Various tensile tests were conducted, and it was found that carbon spring could revert to its original shape upon 80% compression strain and -60% stretching strain with a Poisson's ratio between 0.05 and 0.1. The narrow hysteresis loop of the stress-strain curve indicates a low energy dissipation (energy loss coefficient of about 0.2) because of its negligible interior friction, localized buckling, or cracks during deformation processes. The stretchable mechanical properties of this material allow for great candidates for vibrational and magnetism sensors.
Sources: en.wikipedia.org
There are RGBW LEDs that combine RGB units with a phosphor white LED on the market. Doing so retains the extremely tunable color of RGB LEDs, but allows color rendering and efficiency to be optimized when a color close to white is selected. Some phosphor white LED units are "tunable white", blending two extremes of color temperatures (commonly 2700K and 6500K) to produce intermediate values. This feature allows users to change the lighting to suit the current use of a multifunction room. As illustrated by a straight line on the chromaticity diagram, simple two-white blends will have a pink bias, becoming most severe in the middle. A small amount of green light, provided by another LED, could correct the problem. Some products are RGBWW, i.e. RGBW with tunable white. A final class of white LED with mixed light is dim-to-warm. These are ordinary 2700K white LED bulbs with a small red LED that turns on when the bulb is dimmed. Doing so makes the color warmer, emulating an incandescent light bulb.
==== Lieutenant of the Royal Victorian Order (LVO) ==== Ian Scott Anderson, , Director, The Duke of Edinburgh's Commonwealth Study Conferences. Mark Appleby, Crown Jeweller. Colonel Jeremy David Bagshaw, , Late Coldstream Guards, 534873; lately Chief of Staff, London District, on the occasion of the Coronation of Their Majesties The King and The Queen. Major Grant Vincent Ashley Baker, Gentleman Usher to His Majesty The King. Paul David Baumann, , Receiver-General, Westminster Abbey, on the occasion of the Coronation of Their Majesties The King and The Queen. Charles Harcourt James Davies, , Private Secretary to The Princess Royal. Karen Ross Findlay, Commander, Metropolitan Police Service, on the occasion of the Coronation of Their Majesties The King and The Queen. Dr Michael Terence Isaac, Occupational Health Advisor to the Royal Household. Air Vice-Marshal Richard Howard Lacey, , lately Gentleman Usher to His Majesty The King. Charlotte Elizabeth Martin, , Deputy Head of Ceremonial, Royal Household. Jonathan David Rogerson Martin, Director of Ceremonials, Department for Culture, Media and Sport, on the occasion of the Coronation of Their Majesties The King and The Queen. Ian Donald McCowan, lately Secretary to the Governor-General of Canada. Professor Paul Mealor, Music Advisor, Honours of Scotland Service. Graham Paul Midgley, Head of Royal Travel, Royal Household. Gavin Donald Reid, Music Advisor, Honours of Scotland Service. Paul John Sedwick, Deputy Ranger, Windsor Great Park.
== CLIA-waived tests == Under CLIA, tests and test systems that meet risk, error, and complexity requirements are issued a CLIA certificate of waiver. In November 2007, the CLIA waiver provisions were revised by the United States Congress to make it clear that tests approved by the FDA for home use automatically qualify for CLIA waiver, although many waived tests are not done according to designed protocols – more than 50% of such tests are done incorrectly – and result in medical errors, some with fatal consequences.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.